Advertisement
Advertisement
Promising Phase 2b Advancement of EP-104GI Boosts Buy Rating Amid Positive RESOLVE Trial Results
PremiumRatingsPromising Phase 2b Advancement of EP-104GI Boosts Buy Rating Amid Positive RESOLVE Trial Results
1M ago
Eupraxia Pharmaceuticals Reports Positive Results in EoE Trial and Plans Expansion
Premium
Company Announcements
Eupraxia Pharmaceuticals Reports Positive Results in EoE Trial and Plans Expansion
1M ago
Closing Bell Movers:  Progress Software up 4%, Jefferies slips 1% on earnings
Premium
The Fly
Closing Bell Movers: Progress Software up 4%, Jefferies slips 1% on earnings
2M ago
Eupraxia Pharmaceuticals Prices $70 Million Public Offering
PremiumCompany AnnouncementsEupraxia Pharmaceuticals Prices $70 Million Public Offering
2M ago
Eupraxia Pharmaceuticals 12.727M share Spot Secondary priced at $5.50
Premium
The Fly
Eupraxia Pharmaceuticals 12.727M share Spot Secondary priced at $5.50
2M ago
Closing Bell Movers: ACM Research up 5% after joining S&P SmallCap 600
Premium
The Fly
Closing Bell Movers: ACM Research up 5% after joining S&P SmallCap 600
2M ago
Eupraxia Pharmaceuticals Reports Promising 1-Year Results for EoE Treatment
PremiumCompany AnnouncementsEupraxia Pharmaceuticals Reports Promising 1-Year Results for EoE Treatment
2M ago
Eupraxia Pharmaceuticals announces data from RESOLVE trial in EoE
Premium
The Fly
Eupraxia Pharmaceuticals announces data from RESOLVE trial in EoE
2M ago
Celldex data supports positive Eupraxia thesis, says H.C. Wainwright
Premium
The Fly
Celldex data supports positive Eupraxia thesis, says H.C. Wainwright
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100